论文部分内容阅读
埃博拉病毒自2014年年初开始肆虐以来,相关疫情日益严重。对于埃博拉病毒的预防和治疗,一直以来缺乏有效的药物,多种埃博拉病毒试验性药物都未进入或完成临床阶段。在这些试验性药物中,一种名为ZMapp的试验性抗体药物对两名患者的治疗效果带给了人们极大的期望。本文首先分析了该抗体药物的成份及所述抗体成份的在专利中所公开的关键序列信息以及专利布局,并继而分析了制备该抗体的烟草生产体系,最后给出了目前开展相关抗体研发的建议方向,并基于目前发达国家生物药物领域的开发体系给出了国内相关体系构建的相关建议。
The related epidemic has been aggravating since the Ebola virus began to wreak havoc in early 2014. Ebola virus prevention and treatment has been the lack of effective drugs, a variety of Ebola virus drugs have not yet entered or completed the clinical trial phase. Among these experimental drugs, a test antibody called ZMapp gave great promise for the treatment of two patients. In this paper, we firstly analyzed the composition of the antibody, the key sequence information of the antibody in the patent, and the layout of the patent, and then analyzed the tobacco production system for preparing the antibody. Finally, the current research and development of related antibodies Suggests the direction, and based on the developed countries in the field of biopharmaceutical development system gives the relevant domestic system-related recommendations.